Scholarlink

Objectives <p>This study aimed to evaluate adherence to disease-modifying therapies (DMTs) among patients with multiple sclerosis (MS) and to identify factors influencing compliance, based on perceptions and preferences of both patients and neurologists.</p> Methods <p>Questionnaires were designed by a team of experts, including MS specialists, psychologists, and statisticians, to capture data on treatment adherence and related factors. A total of 1021 MS patients and their neurologists participated. Patients' adherence to oral, injectable, and infusion DMTs was assessed alongside demographic and disease-related characteristics.</p> Results <p>The study included 1021 MS patients with a mean age of 35.69 ± 9.07&#xa0;years. Infusion therapies demonstrated the highest adherence rates (96.6%). Among all patients, 78.9% maintained treatment without interruption, while 56.7% of those who interrupted therapy informed their physicians. Patients with a disease duration of less than one year or more than 10&#xa0;years exhibited lower rates of treatment interruption compared to those with a disease duration of 1–10&#xa0;years (p = 0.032). In the injectable DMT group, significant differences in adherence were noted (p &lt; 0.001). The lowest interruption rate (13.5%) was seen in patients with a disease duration of less than one year, whereas interruption rates were markedly higher (83%) in those with a duration exceeding 16&#xa0;years.</p> Conclusion <p>Improving adherence requires a patient-centered, collaborative approach emphasizing shared decision-making between physicians and patients. Addressing factors that contribute to non-compliance is essential for optimizing treatment outcomes and enhancing long-term disease management in MS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment Adherence in a Large Cohort of Turkish Multiple Sclerosis Population

  • 期刊论文

  • 发表日期：

    2025年2月19日

查看全文
  • Meral Seferoğlu,
  • Bilge Piri Çınar,
  • Ülgen Yalaz Tekan,
  • Fatma Avşar,
  • Pınar Yiğit,
  • Ali Özhan Sıvacı,
  • Serkan Demir,
  • Melih Tütüncü,
  • Haluk Gümüş,
  • Cihat Uzunköprü,
  • Yeşim Beckmann,
  • Gülşen Akman Demir,
  • Ayşe Sağduyu Kocaman,
  • Aksel Siva

摘要

Objectives

This study aimed to evaluate adherence to disease-modifying therapies (DMTs) among patients with multiple sclerosis (MS) and to identify factors influencing compliance, based on perceptions and preferences of both patients and neurologists.

Methods

Questionnaires were designed by a team of experts, including MS specialists, psychologists, and statisticians, to capture data on treatment adherence and related factors. A total of 1021 MS patients and their neurologists participated. Patients' adherence to oral, injectable, and infusion DMTs was assessed alongside demographic and disease-related characteristics.

Results

The study included 1021 MS patients with a mean age of 35.69 ± 9.07 years. Infusion therapies demonstrated the highest adherence rates (96.6%). Among all patients, 78.9% maintained treatment without interruption, while 56.7% of those who interrupted therapy informed their physicians. Patients with a disease duration of less than one year or more than 10 years exhibited lower rates of treatment interruption compared to those with a disease duration of 1–10 years (p = 0.032). In the injectable DMT group, significant differences in adherence were noted (p < 0.001). The lowest interruption rate (13.5%) was seen in patients with a disease duration of less than one year, whereas interruption rates were markedly higher (83%) in those with a duration exceeding 16 years.

Conclusion

Improving adherence requires a patient-centered, collaborative approach emphasizing shared decision-making between physicians and patients. Addressing factors that contribute to non-compliance is essential for optimizing treatment outcomes and enhancing long-term disease management in MS.